{
    "2020-01-29": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis Edges Higher Into Buy Zone Even As Generic Drugs Struggle",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Higher",
                        "Buy Zone",
                        "Generic Drugs",
                        "Struggle"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Rockville biotech opens new HQ as it goes on hiring spree",
                "features": {
                    "keywords": [
                        "Rockville",
                        "biotech",
                        "HQ",
                        "hiring spree"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Phase III",
                        "Atopic Dermatitis",
                        "Primary Goal"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Novartis (NVS) Earnings and Revenues Miss Estimates in Q4",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Earnings",
                        "Revenues",
                        "Miss Estimates",
                        "Q4"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Novartis Stock Is Rising as Earnings Inch Past Forecasts",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Stock",
                        "Rising",
                        "Earnings",
                        "Forecasts"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Earnings",
                        "Hepion",
                        "NASH",
                        "Candidate",
                        "Annovis Bio",
                        "Debut"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Novartis Earnings Narrowly Top; Drug Giant Rises In Buy Zone",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Earnings",
                        "Top",
                        "Drug Giant",
                        "Buy Zone"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Novartis says taxes hit fourth-quarter profit, but sees growth in 2020",
                "features": {
                    "keywords": [
                        "Novartis",
                        "taxes",
                        "fourth-quarter",
                        "profit",
                        "growth",
                        "2020"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Novartis sees no coronavirus disruption amid China growth",
                "features": {
                    "keywords": [
                        "Novartis",
                        "coronavirus",
                        "disruption",
                        "China",
                        "growth"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Novartis sales rise 9% as new medicines provide a boost",
                "features": {
                    "keywords": [
                        "Novartis",
                        "sales",
                        "rise",
                        "new medicines",
                        "boost"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Novartis predicts rising sales and minimal disruption from coronavirus",
                "features": {
                    "keywords": [
                        "Novartis",
                        "rising sales",
                        "minimal disruption",
                        "coronavirus"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-13",
                "original_text": "Novartis/Big Pharma: dosing up",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Big Pharma",
                        "dosing up"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}